Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry

CompletedOBSERVATIONAL
Enrollment

481

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

August 31, 2017

Conditions
Breast Cancer
Trial Locations (17)

14263

Roswell Park Cancer Institute, Buffalo

15102

St. Clair Hospital, Pittsburgh

19047

St. Mary Medical Center, Langhorne

21502

Western Maryland Health System, Cumberland

30033

The Cancer Center at DeKalb Medical, Decatur

33442

University of Miami, Miami

33607

St. Joseph's Women's Hospital, Tampa

44302

Akron General Medical Center, Akron

46321

Community Healthcare System, Munster

46410

Methodist Hospital, Merrillville

48911

Sparrow Cancer Center, Lansing

53226

Aurora Cancer Care, Milwaukee

60555

Cadence Cancer Center, Warrenville

73104

University of Oklahoma, Oklahoma City

92262

Desert Regional Medical Center, Palm Springs

07109

Essex Oncology, Belleville

Unknown

Columbia St. Mary's, Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Agendia

INDUSTRY

NCT02670577 - Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry | Biotech Hunter | Biotech Hunter